Bioversys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. Its lead candidate BV100 is in Phase 3 clinical trials for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir in Phase 2 trials for pulmonary and meningeal tuberculosis, BV200 for Gram-positive S. aureus infections, and BV500 for non-tuberculous mycobacteria infections. BioVersys has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. Founded in 2008, the company is based in Basel, Switzerland.